TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children
Brief Summary: An investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in Burkina Faso and Mali.Three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Pyrimethamine/sulfadoxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children
Brief Summary: An investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in Burkina Faso and Mali.Three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sulphadoxine-pyrimethamine; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine, Drug: Sulphadoxine-pryrimethamine | Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: mefloquine, Drug: IPTi mefloquine | Arm Label: Chlorproguanil dapsone; Type: EXPERIMENTAL; Interventions: Drug: Chlorproguanil-dapsone, Drug: Chlorproguanil dapsone | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil-dapsone; Assigned to Arm(s): Chlorproguanil dapsone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sulphadoxine-pryrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: IPTi mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil dapsone; Assigned to Arm(s): Chlorproguanil dapsone
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
C: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
D: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients
Brief Summary: Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an increased risk of death, a decline in pulmonary function and a significant change in quality of life. Bacteria appear to have an important role in acute exacerbations in chronic bronchitis and COPD. Studies of acute exacerbations in COPD have shown a reduction in bacterial load with prolonged exacerbation-free interval. In addition, recent studies indicate that acquisition of a new strain of H. influenzae, M. catarrhalis, S. pneumoniae or P. aeruginosa are responsible for many of these exacerbations. Chronic inflammation and bacterial infection predispose many patients to frequent and recurrent acute exacerbations.

Mpex believes that intermittent administration of inhaled MP-376 in high risk patients will decrease the incidence of acute exacerbations by both by lowering the organism burden, and resultant inflammation, as well as pre-emptive eradication of any newly acquired bacterial strains.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Intravenous prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral prednisolone; Assigned to Arm(s): N/A
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Sea Buckthorn Oil on Dry Eye
Brief Summary: The objective is to study the effect of sea buckthorn oil on dry eye.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive Capsule | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Hydroeye | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydroeye; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Inactive Capsule; Assigned to Arm(s): 1
B: Arm Label: SB; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sea buckthorn (Hippophaë rhamnoides) oil | Arm Label: PL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparison | Intervention Type: DIETARY_SUPPLEMENT; Name: Sea buckthorn (Hippophaë rhamnoides) oil; Assigned to Arm(s): SB | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparison; Assigned to Arm(s): PL
C: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
D: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome.
Brief Summary: The purpose of this study is to determine whether PD 0299685 is effective in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain, urinary urgency and frequency. At the same time assess the drug's safety and tolerability.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amitriptyline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: PD 0299685 15mg; Type: EXPERIMENTAL; Interventions: Drug: PD 0299685 at 15mg BID | Arm Label: PD 0299685 30mg; Type: EXPERIMENTAL; Interventions: Drug: PD 0299685 at 30mg BID | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for PD 0299685 | Intervention Type: DRUG; Name: PD 0299685 at 15mg BID; Assigned to Arm(s): PD 0299685 15mg | Intervention Type: DRUG; Name: PD 0299685 at 30mg BID; Assigned to Arm(s): PD 0299685 30mg | Intervention Type: DRUG; Name: placebo for PD 0299685; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Arm Label: Low energy shock wave; Type: EXPERIMENTAL; Interventions: Device: Low energy shock wave | Intervention Type: DEVICE; Name: Low energy shock wave; Assigned to Arm(s): Low energy shock wave | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AQX-1125; Type: EXPERIMENTAL; Interventions: Drug: AQX-1125 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AQX-1125; Assigned to Arm(s): AQX-1125 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychotherapies for Chronic Post-Traumatic Stress Disorder
Brief Summary: This study will examine whether interpersonal psychotherapy is as effective in treating post-traumatic stress disorder as the established therapies of prolonged exposure and relaxation.


Options:
A: Arm Label: 1 Interpersonal Psychotherapy (IPT); Type: EXPERIMENTAL; Interventions: Behavioral: Interpersonal Psychotherapy | Arm Label: 2 Prolonged Exposure (PE); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolonged Exposure Therapy | Arm Label: 3 Relaxation therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation Therapy | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): 1 Interpersonal Psychotherapy (IPT) | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy; Assigned to Arm(s): 2 Prolonged Exposure (PE) | Intervention Type: BEHAVIORAL; Name: Relaxation Therapy; Assigned to Arm(s): 3 Relaxation therapy
B: Arm Label: Waitlist+EducAid; Type: ACTIVE_COMPARATOR; Interventions: Other: EducAid educational programming | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: YRI only; Type: EXPERIMENTAL; Interventions: Behavioral: YRI, Other: EducAid educational programming | Arm Label: YRI+EducAid; Type: EXPERIMENTAL; Interventions: Behavioral: YRI, Other: EducAid educational programming | Intervention Type: BEHAVIORAL; Name: YRI; Assigned to Arm(s): YRI only, YRI+EducAid | Intervention Type: OTHER; Name: EducAid educational programming; Assigned to Arm(s): Waitlist+EducAid, YRI only, YRI+EducAid
C: Arm Label: advocacy intervention; Type: EXPERIMENTAL; Interventions: Behavioral: advocacy intervention | Arm Label: Usual community services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual community services | Intervention Type: BEHAVIORAL; Name: advocacy intervention; Assigned to Arm(s): advocacy intervention | Intervention Type: BEHAVIORAL; Name: usual community services; Assigned to Arm(s): Usual community services
D: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Trial of Gene Expression Modulation by Intervention With Nutrition and Lifestyle
Brief Summary: RATIONALE: Learning about changes in DNA over time in patients with prostate cancer undergoing diet and lifestyle changes may help doctors learn about the long-term effects of these changes on disease progression.

PURPOSE: This clinical trial is studying nutrition and lifestyle changes in patients with previously untreated stage I or stage II prostate cancer.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise Arm
B: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Walking Program; Type: EXPERIMENTAL; Interventions: Other: Walking Program | Intervention Type: OTHER; Name: Walking Program; Assigned to Arm(s): Walking Program
C: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: proteomic profiling; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: reverse transcriptase-polymerase chain reaction; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: medical chart review; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: support group therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: therapeutic dietary intervention; Assigned to Arm(s): N/A
D: Arm Label: Exercise and whole grain rye; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Whole grain rye, Behavioral: Recommendations | Arm Label: No prescriptions; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendations | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise and whole grain rye | Intervention Type: BEHAVIORAL; Name: Whole grain rye; Assigned to Arm(s): Exercise and whole grain rye | Intervention Type: BEHAVIORAL; Name: Recommendations; Assigned to Arm(s): Exercise and whole grain rye, No prescriptions

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Stress Management and Exercise Intervention During Cancer Chemotherapy
Brief Summary: Chemotherapy adversely affects quality of life in cancer patients. Both stress management training and exercise training have been shown to improve quality of life. These two types of training have not been directly compared for chemotherapy patients.

This study seeks to evaluate the separate and combined effects of stress management training and exercise training on quality of life during chemotherapy treatment. Participants receive either a home-based, self-administered program in 1 of 3 types (stress management, exercise, or stress management + exercise) or usual care (reading materials). It is hypothesized that the combined program (stress management + exercise) will be significantly associated with better quality of life than the usual care group, the exercise only group, and the stress management only group. All participants are assessed at 3 timepoints: before they begin chemotherapy, 6 weeks after their first chemotherapy infusion, and 12 weeks after their first infusion.


Options:
A: Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise Arm
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stress Management training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Combined stress management and exercise training | Intervention Type: BEHAVIORAL; Name: Stress Management training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Exercise Training; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Combined stress management and exercise training; Assigned to Arm(s): 4
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction.
Brief Summary: Urinary incontinence is any involuntary loss of urine. During gestation, hormonal and mechanical factors favor the incidence of urinary loss that may persist after delivery in up to 50% of women. Gestational urine loss can be prevented or treated during pregnancy with physical therapy. Pregnancy and delivery have been widely deemed important risk factors that should be assessed while developing preventive and curative treatments for both female urinary incontinence and pelvic floor muscle dysfunction. Pelvic floor muscle exercises, led by skilled physical therapists, can prevent, reduce, or even cure involuntary urine loss as well as pelvic floor muscle dysfunction. Within this framework, developing a low-cost, easy-to-perform method for the treatment of urinary incontinence and pelvic floor muscle dysfunction, with a preventive or curative approach, is considered necessary. The overall objective of this study is to assess the effects of pelvic floor exercises during pregnancy on pelvic floor muscles and urinary continence. Secondary aims include determining whether exercises change pelvic floor muscle function; if changing pelvic floor muscle function reduces the occurrence of urinary incontinence; developing and applying a manual guide; and determining whether the physical therapy guide is well accepted, easily understandable and reproducible.


Options:
A: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Workshop | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Workshop; Assigned to Arm(s): Intervention
C: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise classes with pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise classes with pelvic floor muscle training; Assigned to Arm(s): Exercise group
D: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise

Answer: A